Union health minister reiterates its commitment to implement NPCDCS

Union health minister of State Ashwini Kumar Choubey reiterated government’s commitment to implement National Programme for Prevention and control of cancer, diabetes, cardiovascular diseases and stroke (NPCDCS), with focus on strengthening infrastructure.

It stated that the government will also renew its focus for human resource development, health promotion and awareness generation, early diagnosis, management and referral to an appropriate level institution for effective treatment.

Choubey stated that to tackle the challenge of non communicable diseases (NCD), including cancer, 616 NCD clinics at district level and 3,827 NCD clinics at community health centre level have been set up under NPCDCS.

Population level initiative has also been taken up for prevention, control and screening for common NCDs (diabetes, hypertension and common cancers such as oral, breast and cervical cancer has also been rolled out under the National Health Mission (NHM) in over 215 districts.

To enhance the facilities for tertiary care of cancer, the central government is also implementing strengthening of tertiary care for cancer scheme, under which setting up of 19 state cancer institutes and 20 tertiary care cancer centres have been approved.

Government has also taken several measures to discourage the use of tobacco products, which is one of the key risk factors of cancer, besides initiative to promote healthy lifestyles through healthy eating and regular physical activity.

"Further, oncology is one of the focus areas in case of new AIIMS and many upgraded institutions under Pradhan MantriSwasthya Suraksha Yojana (PMSSY). Setting up of National Cancer Institute at Jhajjar in Haryana and strengthening of Chittaranjan National Cancer Institute, Kolkata are also steps in the same direction. Screening of common NCDs including three common cancers such as oral, breast and cervical is also an integral part of service delivery under Ayushman Bharat health and wellness centres," he stated.

Cancer is diagnosed and treated at various levels in the health care system. In government hospitals, treatment is either free or highly subsidised. Treatment of cancers is also available under Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PMJAY).

 Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=121002&sid=2
Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=121002&sid=2

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more